Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon (ReLoaDeD)
Sponsor: Bayer
This observational or N/A phase trial investigates Atrial Fibrillation and is currently completed. Bayer leads this study, which shows 16 recorded versions since 2018 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
16 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Dec 2020 — Jan 2021 [monthly]
Completed
-
Sep 2020 — Dec 2020 [monthly]
Completed
▶ Show 11 earlier versions
-
Jan 2020 — Sep 2020 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Dec 2019 — Jan 2020 [monthly]
Active Not Recruiting
-
Nov 2019 — Dec 2019 [monthly]
Active Not Recruiting
Status: Not Yet Recruiting → Active Not Recruiting
-
Sep 2019 — Nov 2019 [monthly]
Not Yet Recruiting
Status: Completed → Not Yet Recruiting
-
Jan 2019 — Sep 2019 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Dec 2018 — Jan 2019 [monthly]
Active Not Recruiting
-
Nov 2018 — Dec 2018 [monthly]
Active Not Recruiting
-
Oct 2018 — Nov 2018 [monthly]
Active Not Recruiting
-
Sep 2018 — Oct 2018 [monthly]
Active Not Recruiting
-
Aug 2018 — Sep 2018 [monthly]
Active Not Recruiting
-
Jul 2018 — Aug 2018 [monthly]
Active Not Recruiting
First recorded
Jun 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- Janssen Research & Development, LLC
For direct contact, visit the study record on ClinicalTrials.gov .